Showing results (31-40 of 3,350) with videos related to

Sort By:
Pageof 335
The Lancet. Oncology|January 22, 2011
Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studiesAlex J Mitchell, Melissa Chan, Henna Bhatti, et al.
The Lancet. Oncology|February 3, 2009
Germ-line DNA polymorphisms and susceptibility to differentiated thyroid cancerElisabeth Adjadj, Martin Schlumberger, Florent de Vathaire
The Lancet. Oncology|February 3, 2009
Preoperative treatment and surgery in gastric cancer: friends or foes?Domenico D'Ugo, Stefano Rausei, Alberto Biondi, et al.
The Lancet. Oncology|November 29, 2008
Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published dataAndreas Hackethal, Doerthe Brueggmann, Michael K Bohlmann, et al.
The Lancet. Oncology|October 12, 2010
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continuesMichel Delforge, Joan Bladé, Meletios A Dimopoulos, et al.
The Lancet. Oncology|April 15, 2011
Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO)Marcos Ballester, Gil Dubernard, Fabrice Lécuru, et al.
The Lancet. Oncology|March 25, 2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyMiguel Martin, Henri Roche, Tamas Pinter, et al.
The Lancet. Oncology|February 25, 2011
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation studyIrene M Ghobrial, Edie Weller, Ravi Vij, et al.
The Lancet. Oncology|March 29, 2011
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 studyStephen M Ansell, Hui Tang, Paul J Kurtin, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
Pageof 335